Clinical trial

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

NCT03373227

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Envarsus Normalized identity: EnvarsusView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-12-04

PhasePHASE2

Conditions

Heart Transplant Rejectionunresolved

Graft Failureunresolved

Compliance, Patientunresolved

Interventions

EnvarsusDRUG · verified · RxNorm: Envarsus

Sponsors & collaborators

Baylor Research Institutelead sponsor

Mapped research locations

DallasTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03373227 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.